Cargando…
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib
SIMPLE SUMMARY: Proteasome inhibitors are currently used in the treatment of certain blood cancers, and clinical trials to treat solid tumors, including liver cancer, have also been conducted. However, different malignancies are not equally susceptible to proteasome inhibitors, and resistance to the...
Autores principales: | Örd, Tiit, Örd, Daima, Kaikkonen, Minna U., Örd, Tõnis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150958/ https://www.ncbi.nlm.nih.gov/pubmed/34066165 http://dx.doi.org/10.3390/cancers13102341 |
Ejemplares similares
-
Genome-wide census of ATF4 binding sites and functional profiling of trait-associated genetic variants overlapping ATF4 binding motifs
por: Örd, Tiit, et al.
Publicado: (2023) -
A human-specific VNTR in the TRIB3 promoter causes gene expression variation between individuals
por: Örd, Tiit, et al.
Publicado: (2020) -
Trib3 Is Developmentally and Nutritionally Regulated in the Brain but Is Dispensable for Spatial Memory, Fear Conditioning and Sensing of Amino Acid-Imbalanced Diet
por: Örd, Tiit, et al.
Publicado: (2014) -
Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis
por: Butcher, Lee, et al.
Publicado: (2017) -
Amino Acid Availability Controls TRB3 Transcription in Liver through the GCN2/eIF2α/ATF4 Pathway
por: Carraro, Valérie, et al.
Publicado: (2010)